Screening to Improve Survival in AL Amyloidosis
Smoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceThe purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM)...
Multiple MyelomaSmoldering Multiple Myeloma1 moreThe key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or...
Multiple Myeloma and Plasma Cell NeoplasmPrecancerous ConditionRATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma. PURPOSE: This phase II trial is studying how well green tea extract works in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma.
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma1 moreEscalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the study is to determine if the Omega 3 supplementation will help prevent or delay progression of the disease to a stage that requires treatment.
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined...
Precancerous ConditionThis study was done to find out if the investigational medication, rituximab, could help relieve the symptoms of peripheral neuropathy (such as numbness [abnormal protein in the blood] and weakness of the lower and upper extremities) in people who have monoclonal gammopathy of undetermined significance and people with a symptomatic or smoldering Waldestrom macroglobulinemia. Rituximab is an antibody which attacks a particular type of white blood cell (B Cell). By targeting the B-cells which make the abnormal protein which is involved in causing the nerve trouble, it is hoped that damage to nerve fibers will be stopped and improvement will be allowed to proceed.
RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal...
PolyneuropathyPolyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory...
Monoclonal Gammopathy of Undetermined SignificanceMultiple Myeloma1 morePatients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS. The aim of the study is to search for inflammatory pathway that may be activated in case MGIS and to search if the genetic of tumoral cell could explain those activations.
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy...
Monoclonal Gammopathy of Undetermined SignificanceMultiple Myeloma1 moreThe purpose of this study is to determine if siltuximab has an effect on the heart function measured by ECG recordings and more specifically to determine if siltuximab has an effect on the QT interval in patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) or Indolent Multiple Myeloma (IMM). The study will also look to see if siltuximab may be useful in treating patients with MGUS, SMM or IMM.
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Accelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated Leukemia84 moreDrugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction
Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction...
Monoclonal Gammopathy of Undetermined SignificanceScreening study to determine incidence of MGUS in this patient population